DURECT is leveraging its epigenetic regulator program and proprietary drug delivery technologies to develop novel and lifesaving therapies for a wide range of diseases with few current treatment options.
DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.
DURECT's Investor section provides comprehensive information to existing and potential stockholders, including up-to-date stock information, financial reports, investor events and more.
The first endogenous epigenetic regulator clinically tested for the treatment of acute organ injury and chronic liver diseases.
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022
DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs
May 4, 2022
April 27, 2022